This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nieuwlaat, W.-A. Articles by Huysmans, D. A. Search for Related Content PubMed PubMed Citation Articles by Nieuwlaat, W.-A. Articles by Huysmans, D. A.

Pretreatment with Recombinant Human TSH Changes the Regional Distribution of Radioiodine on Thyroid Scintigrams of Nodular Goiters

Department of Nuclear Medicine (W.-A.N., F.S.-P., D.A.H.), Catharina Hospital, 5602 ZA Eindhoven, The Netherlands; and Departments of Endocrinology (W.-A.N., A.R.H.) and Nuclear Medicine (F.H.C.), University Medical Center Nijmegen, 6500 HB Nijmegen, The Netherlands

Address all correspondence and requests for reprints to: Dr. D. Huysmans, Department of Nuclear Medicine, Catharina Hospital, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands.

Abstract

In a recent study, we demonstrated that pretreatment with a single, low dose of recombinant human TSH (rhTSH) doubles 24-h thyroid radioactive iodine uptake in patients with nodular goiter. The purpose of the present study was to investigate whether rhTSH pretreatment induces changes in the regional distribution of radioiodine as visualized on thyroid scintigrams in these patients.

Anterior planar thyroid ¹²³I scintigrams were obtained in 26 patients with a nodular goiter (23 women and 3 men; age, 62 ± 9 yr, mean ± SD; thyroid weight, 165 ± 72 g) 24 h after administration of a diagnostic dose of radioiodine. All patients were studied twice: first, without rhTSH pretreatment (baseline study), and second, after an im injection of 0.01 mg (n = 10) or 0.03 mg rhTSH (n = 16), given 24 h before radioiodine administration (rhTSH study). For quantification of regional differences in radioiodine uptake, a region of interest method was used.

Upon visual inspection, baseline scintigrams showed a heterogeneous uptake of radioiodine. In general, rhTSH scintigrams also showed heterogeneous radioiodine uptake. In some patients, the distribution of radioiodine in the rhTSH scintigram was considerably more homogeneous than in the baseline scintigram. In a few patients, originally "cold" areas had changed into "hot" ones, whereas originally hot areas had changed into cold ones. Quantification of regional radioiodine uptake showed that pretreatment with rhTSH caused a larger increase in radioiodine uptake in relatively cold areas and a smaller increase in radioiodine uptake in relatively hot areas, compared with the increase in radioiodine uptake in the entire thyroid. In patients with a baseline serum TSH level of 0.5 mU/liter or lower, the increase in radioiodine uptake in relatively cold areas was significantly larger than in patients with a baseline serum TSH level higher than 0.5 mU/liter.

In conclusion, a single, low dose of rhTSH not only doubled 24-h radioactive iodine uptake but also caused a more homogeneous distribution of radioiodine within the thyroid gland in patients with a nodular goiter by stimulating radioiodine uptake in relatively cold areas more than in relatively hot areas. This was most marked in patients with a low baseline serum TSH level. Our data suggest that pretreatment with rhTSH may improve the efficacy of radioiodine treatment for volume reduction of nodular goiters, especially in patients with a low baseline serum TSH level.

This article has been cited by other articles:

				V. E. Nielsen, S. J. Bonnema, H. Boel-Jorgensen, P. Grupe, and L. Hegedus Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial. Arch Intern Med, July 24, 2006; 166(14): 1476 - 1482. [Abstract] [Full Text] [PDF]

				O. Cohen, J. Ilany, C. Hoffman, D. Olchovsky, S. Dabhi, A. Karasik, E. Goshen, G. Rotenberg, and S T. Zwas Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients Eur. J. Endocrinol., February 1, 2006; 154(2): 243 - 252. [Abstract] [Full Text] [PDF]

				S. Pena, S. Arum, M. Cross, B. Magnani, E. N. Pearce, M. E. Oates, and L. E. Braverman 123I Thyroid Uptake and Thyroid Size at 24, 48, and 72 Hours after the Administration of Recombinant Human Thyroid-Stimulating Hormone to Normal Volunteers J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 506 - 510. [Abstract] [Full Text] [PDF]

				C. C. Albino, C. O. Mesa Jr., M. Olandoski, C. E. Ueda, L. C. Woellner, C. A. Goedert, A. M. Souza, and H. Graf Recombinant Human Thyrotropin as Adjuvant in the Treatment of Multinodular Goiters with Radioiodine J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2775 - 2780. [Abstract] [Full Text] [PDF]

				V. E. Nielsen, S. J. Bonnema, H. Boel-Jorgensen, A. Veje, and L. Hegedus Recombinant Human Thyrotropin Markedly Changes the 131I Kinetics during 131I Therapy of Patients with Nodular Goiter: An Evaluation by a Randomized Double-Blinded Trial J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 79 - 83. [Abstract] [Full Text] [PDF]

				W.-A. Nieuwlaat, A. R. Hermus, H. A. Ross, W. C. Buijs, M. A. Edelbroek, J. W. Bus, F. H. Corstens, and D. A. Huysmans Dosimetry of Radioiodine Therapy in Patients with Nodular Goiter After Pretreatment with a Single, Low Dose of Recombinant Human Thyroid-Stimulating Hormone J. Nucl. Med., April 1, 2004; 45(4): 626 - 633. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, V. E. Nielsen, and L. Hegedus Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6113 - 6114. [Full Text] [PDF]

				W.-A. Nieuwlaat, D. A. Huysmans, H. C. van den Bosch, C. G. (F. Sweep, H. A. Ross, F. H. Corstens, and A. R. Hermus Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3121 - 3129. [Abstract] [Full Text] [PDF]

				R. J. Robbins and A. K. Robbins Recombinant Human Thyrotropin and Thyroid Cancer Management J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1933 - 1938. [Full Text] [PDF]

				L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]